Radiopharm Theranostics Limited (ASX:RAD)

Market Cap	60.68M
Revenue (ttm)	330.63K
Net Income (ttm)	-43.00M
Shares Out	2.33B
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	482,848
Average Volume	2,904,847
Open	0.0270
Previous Close	0.0260
Day's Range	0.0260 - 0.0270
52-Week Range	0.0190 - 0.0480
Beta	0.84
RSI	59.51
Earnings Date	May 29, 2025

About Radiopharm Theranostics

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RAD

Financial Performance

In 2024, Radiopharm Theranostics's revenue was 1.96 million, a decrease of -68.46% compared to the previous year's 6.21 million. Losses were -47.95 million, 38.5% more than in 2023.